Depending on the availability of funding, it would be optimal for KRAS testing to begin immediately following a diagnosis of metastatic disease; currently however, testing can only be undertaken when the Oncologist is considering third-line therapy. This evidence concerns the gene KRAS and metastatic neoplasm.